Sign In
Buy ARMP
$7.01
+0.140 (+2.04%)
At Close: Jun 23, 2026
Armata Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
07:30am, Thursday, 05'th Sep 2024
LOS ANGELES , Sept. 5, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on the development of high-purity, pathogen-
Armata Pharmaceuticals Announces Presentation at the 2024 Military Health System Research Symposium
07:30am, Monday, 26'th Aug 2024
LOS ANGELES , Aug. 26, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on the development of high-purity, pathogen-
LOS ANGELES, Aug. 15, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on the development of high-purity, pathogen-s
Armata Pharmaceuticals Announces Second Quarter 2024 Results and Provides Corporate Update
04:05pm, Tuesday, 13'th Aug 2024
LOS ANGELES , Aug. 13, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on high-purity, pathogen-specific bacterioph
Phase 1b/2a diSArm trial evaluating AP-SA02 as a potential treatment for complicated Staphylococcus aureus bacteremia LOS ANGELES , July 30, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE
Tailwind is evaluating inhaled AP-PA02 in non-cystic fibrosis bronchiectasis (NCFB), its second patient population, following successful evaluation in patients with cystic fibrosis (SWARM-P.a.) in 202
Armata Pharmaceuticals Announces Presentation at Viruses of Microbes 2024
04:05pm, Wednesday, 10'th Jul 2024
LOS ANGELES , July 10, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-pu
Armata Pharmaceuticals Announces First Quarter 2024 Results and Provides Corporate Update
04:01pm, Tuesday, 07'th May 2024
LOS ANGELES , May 7, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on high-purity, pathogen-specific bacteriophag
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Results and Provides Corporate Update
04:05pm, Thursday, 21'st Mar 2024
LOS ANGELES , March 21, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on high-purity, pathogen-specific bacteriop
Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva
04:01pm, Monday, 04'th Mar 2024
Proceeds to be used to continue to advance rigorously designed clinical trials of Armata's high purity phage-based therapeutic candidates LOS ANGELES , March 4, 2024 /PRNewswire/ -- Armata Pharmaceuti
Armata Pharmaceuticals Announces Presentation at the 6th Annual Bacteriophage Therapy Summit
07:00am, Wednesday, 21'st Feb 2024
LOS ANGELES , Feb. 21, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeut
Armata Pharmaceuticals Announces Third Quarter 2023 Results and Provides Corporate Update
04:00pm, Tuesday, 14'th Nov 2023
LOS ANGELES , Nov. 14, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeut
LOS ANGELES , Oct. 30, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeut
Armata Pharmaceuticals Announces Presentation at Phage Futures: Global Digital Summit 2023
08:00am, Thursday, 19'th Oct 2023
LOS ANGELES , Oct. 19, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata"), a clinical stage biotechnology company focused on pathogen-specific bacteriophage therapeuti
Initiation of the Phase 2a portion follows DRC review of positive safety and tolerability data from recently completed Phase 1b portion Study being conducted in partnership with the U.S. Department of
